-->

Tag: PD-L1 CPS ≥1 immunotherapy

Home / PD-L1 CPS ≥1 immunotherapy

Categories

Pembrolizumab is approved by the USFDA for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

On March 19, 2025, the Food and Drug Administration officially approved pembrolizumab (Keytruda, Merck) to be used along with trastuzumab and chemotherapy that includes fluoropyrimidine and platinum f...
pd-l1-cps-%e2%89%a51-immunotherapy

Scan the code